The patentability of biotech inventions should meet substantive requirements such as novelty, inventive step and industrial applicability, but EPO developments suggest that formalities are increasingly important.
The rules for filing European divisional applications have been drastically limited for applicants for two years.
Since April 1, 2010, the rules for filing a European divisional patent application have been restricted—rules 36(1)(a) and 36(1) (b). Under rule 36(1)(a), an applicant has 24 months to file a European divisional calculated from the first European office action of the earliest application, the so-called ‘voluntary divisional’.
You need a subscription to continue reading this content.
To access the full archive, digital magazines and special reports you will need to take out a paid subscription.
News stories up to a week old and feature articles on the day of publication are accessible with a BASIC FREE ACCOUNT.
If you have already subscribed please login.
If you have any technical issues please email tech support.
For access to the complete website, archive, and to receive print publications, choose '12 MONTH SUBSCRIPTION'. For a free, two-week trial with full access, select ‘TWO WEEK FREE TRIAL’; and for basic access to the latest news on the website and weekly email news alerts choose the 'BASIC FREE ACCOUNT' registration.
invention, biotechnology, EPO, industrial applicability